None listed
Conditions
Interventions
Intervention1: Clinical Pharmacist Intervention: Participants will be screened for non alcoholic fatty liver disease using the Hepatic Steatosis Index. High risk participants will receive pharmacist l
Sponsors
T Kowshik
Eligibility
Inclusion criteria
Inclusion criteria: 1. Adults aged twenty to sixty years attending the hospital outpatient department 2. Patients identified as being at risk of non alcoholic fatty liver disease including those with obesity or diabetes mellitus 3. Patients who are willing to participate in the study and able to provide written informed consent. 4. Patients who are available and willing to receive clinical pharmacist led lifestyle counselling and attend follow up visits during the study period
Exclusion criteria
Exclusion criteria: 1. Patients with known liver disease including viral hepatitis or alcohol related liver disease or autoimmune liver disease 2. Patients with a history of major surgery involving the liver or gastrointestinal tract that may interfere with study outcomes 3. Patients with a history of alcohol intake 4. Pregnant women or lactating women 5. Patients who are currently undergoing structured diet therapy or exercise programs or treatment for non alcoholic fatty liver disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in Hepatic Steatosis Index (HSI) from baseline to follow-up between standard care and clinical pharmacist led lifestyle counseling groups.Timepoint: Baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in liver enzymes (ALT, AST), anthropometric parameters (BMI, body weight) and proportion of participants showing improvement in HSI and adherence to lifestyle modification advice.Timepoint: Baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks | — |
Countries
India
Contacts
Public ContactDr J Vasudha
Balaji College Of Phamacy
Outcome results
None listed